Related Experiment Video

Updated: Aug 23, 2025

Author Spotlight: Studying Clinical Characters and Epilepsy Outcomes After Frontal Disconnection in Patients with MOGHE
06:04

Author Spotlight: Studying Clinical Characters and Epilepsy Outcomes After Frontal Disconnection in Patients with MOGHE

Published on: August 16, 2024

990

Neurocognitive effects of Moyamoya disease and concomitant epilepsy

Elizabeth R Wallace1, Lisa M Koehl2

  • 1Department of Psychology, University of Kentucky, 171 Funkhouser Drive, Lexington, KY 40508, USA.

Cerebral Circulation - Cognition and Behavior
|November 3, 2022
PubMed
Abstract

Insights

Moyamoya disease (MMD) can cause significant cognitive decline, including executive dysfunction and memory deficits, particularly in adults. This case highlights the need to consider epilepsy and other neurological factors when assessing MMD-related cognitive changes.

Area of Science:

  • Neurology
  • Neuroscience
  • Cerebrovascular Medicine

Background:

  • Moyamoya disease (MMD) is a rare cerebrovascular disorder causing strokes and hypoperfusion.
  • Seizures and cognitive changes, particularly executive dysfunction, are observed in MMD, especially post-surgery.
  • Research on adult MMD neurocognition remains limited.

Observation:

  • This case report presents a detailed neurocognitive evaluation of an adult MMD patient with epilepsy.
  • The patient exhibited a distinct dysexecutive pattern.
  • Atypically poor visual and verbal memory performance was noted.

Findings:

  • The MMD patient demonstrated significant affective symptoms.
  • Substantial functional decline was reported by the patient.
  • Neurocognitive assessment revealed a prominent dysexecutive pattern and memory impairments.

Implications:

  • This case provides valuable insights into unique neurocognitive profiles in adult MMD.
  • It emphasizes the critical role of considering neurological comorbidities, such as epilepsy, in MMD.
  • Understanding these complex interactions is crucial for managing adult MMD patients.
Keywords:
CognitiveEpilepsyExecutive functionMoyamoyaVascular

More Related Videos

Network Analysis of the Default Mode Network Using Functional Connectivity MRI in Temporal Lobe Epilepsy12:09

Network Analysis of the Default Mode Network Using Functional Connectivity MRI in Temporal Lobe Epilepsy

Published on: August 5, 2014

18.1K
A Multimodal Imaging- and Stimulation-based Method of Evaluating Connectivity-related Brain Excitability in Patients with Epilepsy08:23

A Multimodal Imaging- and Stimulation-based Method of Evaluating Connectivity-related Brain Excitability in Patients with Epilepsy

Published on: November 13, 2016

11.3K

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
246
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
541
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
248
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
538
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
482
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
410